Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders VANCOUVER, BC, Oct. 19, 2021 /CNW/ – October 19, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders…


Previous articlePT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood
Next articlePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products